Ataciguat

DRUG3 trials

Sponsors

Kardigan Inc., Jordan D. Miller, Ph.D., Kardigan, Inc.

Conditions

Aortic Valve StenosisModerate Aortic Valve StenosisModerate Calcific Aortic Valve Stenosis (CAVS)

Phase 1

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

CompletedNCT02049203

Jordan D. Miller, Ph.D.Aortic Valve Stenosis

Start: 2014-01-31End: 2015-03-31Updated: 2016-07-07

Phase 2

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

RecruitingNCT07001800

Kardigan, Inc.Moderate Aortic Valve Stenosis

Start: 2025-06-27End: 2030-09-30Target: 1276Updated: 2026-07-06

Phase 3

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)

Not yet recruitingCTIS2025-522176-86-01

Kardigan Inc.Moderate Calcific Aortic Valve Stenosis (CAVS)

Target: 293Updated: 2026-06-10

Related Papers

Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy

Circulation2025-02-2412 citations